LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 2 of total 2

Search options

  1. Article: Colorectal Cancer Survivors Suffering From Sensory Chemotherapy-Induced Peripheral Neuropathy Are Not a Homogenous Group: Secondary Analysis of Patients' Profiles With Oxaliplatin-Induced Peripheral Neuropathy.

    Kerckhove, Nicolas / Selvy, Marie / Lambert, Céline / Gonneau, Coralie / Feydel, Gabrielle / Pétorin, Caroline / Vimal-Baguet, Agnès / Melnikov, Sergey / Kullab, Sharif / Hebbar, Mohamed / Bouché, Olivier / Slimano, Florian / Bourgeois, Vincent / Lebrun-Ly, Valérie / Thuillier, Frédéric / Mazard, Thibault / Tavan, David / Benmammar, Kheir Eddine / Monange, Brigitte /
    Ramdani, Mohamed / Péré-Vergé, Denis / Huet-Penz, Floriane / Bedjaoui, Ahmed / Genty, Florent / Leyronnas, Cécile / Busserolles, Jérôme / Trévis, Sophie / Pinon, Vincent / Pezet, Denis / Balayssac, David

    Frontiers in pharmacology

    2021  Volume 12, Page(s) 744085

    Abstract: Oxaliplatin, a pivotal drug in the management of colorectal cancer, causes chemotherapy-induced peripheral neuropathy (CIPN) in a third of cancer survivors. Based on a previous cross-sectional study assessing oxaliplatin-related sensory CIPN in ... ...

    Abstract Oxaliplatin, a pivotal drug in the management of colorectal cancer, causes chemotherapy-induced peripheral neuropathy (CIPN) in a third of cancer survivors. Based on a previous cross-sectional study assessing oxaliplatin-related sensory CIPN in colorectal cancer survivors, a secondary analysis was designed to explore the possibility that different clusters of patients may co-exist among a cohort of patients with oxaliplatin-related CIPN. Other objectives were to characterize these clusters considering CIPN severity, anxiety, depression, health-related quality of life (HRQOL), patients' characteristics and oxaliplatin treatments. Among the 96 patients analyzed, three clusters were identified (cluster 1: 52, cluster 2: 34, and cluster 3: 10 patients). Clusters were significantly different according to CIPN severity and the proportion of neuropathic pain (cluster 1: low, cluster 2: intermediate, and cluster 3: high). Anxiety, depressive disorders and HRQOL alteration were lower in cluster 1 in comparison to clusters 2 and 3, but not different between clusters 2 and 3. This study underlines that patients with CIPN are not a homogenous group, and that CIPN severity is associated with psychological distress and a decline of HRQOL. Further studies are needed to explore the relation between clusters and CIPN management.
    Language English
    Publishing date 2021-11-04
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2587355-6
    ISSN 1663-9812
    ISSN 1663-9812
    DOI 10.3389/fphar.2021.744085
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: Long-Term Prevalence of Sensory Chemotherapy-Induced Peripheral Neuropathy for 5 Years after Adjuvant FOLFOX Chemotherapy to Treat Colorectal Cancer: A Multicenter Cross-Sectional Study.

    Selvy, Marie / Pereira, Bruno / Kerckhove, Nicolas / Gonneau, Coralie / Feydel, Gabrielle / Pétorin, Caroline / Vimal-Baguet, Agnès / Melnikov, Sergey / Kullab, Sharif / Hebbar, Mohamed / Bouché, Olivier / Slimano, Florian / Bourgeois, Vincent / Lebrun-Ly, Valérie / Thuillier, Frédéric / Mazard, Thibault / Tavan, David / Benmammar, Kheir Eddine / Monange, Brigitte /
    Ramdani, Mohamed / Péré-Vergé, Denis / Huet-Penz, Floriane / Bedjaoui, Ahmed / Genty, Florent / Leyronnas, Cécile / Busserolles, Jérôme / Trevis, Sophie / Pinon, Vincent / Pezet, Denis / Balayssac, David

    Journal of clinical medicine

    2020  Volume 9, Issue 8

    Abstract: 1) Background: Oxaliplatin is among the most neurotoxic anticancer drugs. Little data are available on the long-term prevalence and consequences of chemotherapy-induced peripheral neuropathy (CIPN), even though the third largest population of cancer ... ...

    Abstract (1) Background: Oxaliplatin is among the most neurotoxic anticancer drugs. Little data are available on the long-term prevalence and consequences of chemotherapy-induced peripheral neuropathy (CIPN), even though the third largest population of cancer survivors is made up of survivors of colorectal cancer. (2) Methods: A multicenter, cross-sectional study was conducted in 16 French centers to assess the prevalence of CIPN, as well as its consequences (neuropathic pain, anxiety, depression, and quality of life) in cancer survivors during the 5 years after the end of adjuvant oxaliplatin chemotherapy. (3) Results: Out of 406 patients, the prevalence of CIPN was 31.3% (95% confidence interval: 26.8-36.0). Little improvement in CIPN was found over the 5 years, and 36.5% of patients with CIPN also had neuropathic pain. CIPN was associated with anxiety, depression, and deterioration of quality of life. None of the patients with CIPN were treated with duloxetine (recommendation from American Society of Clinical Oncology), and only 3.2%, 1.6%, and 1.6% were treated with pregabalin, gabapentin, and amitriptyline, respectively. (4) Conclusions: Five years after the end of chemotherapy, a quarter of patients suffered from CIPN. The present study showed marked psychological distress and uncovered a failure in management in these patients.
    Language English
    Publishing date 2020-07-27
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2662592-1
    ISSN 2077-0383
    ISSN 2077-0383
    DOI 10.3390/jcm9082400
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top